Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
WHWK
SellHot AirWhitehawk Therapeutics, Inc. · Healthcare · United States · $263M · Avg Vol: $1M/d
COMPANY DESCRIPTION
Whitehawk Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies and targeted treatments for oncology and inflammatory diseases. The company's competitive position is driven by its proprietary drug discovery platform and intellectual property surrounding specific cellular pathways. It operates as a high-risk, research-driven biotechnology firm seeking strategic partnerships for clinical development.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 15.2M | 24.4M | 26.0M | 7.1M | -22.3% | — | — | — | — |
| EPS | -1.33 | -1.21 | -1.18 | -0.33 | — | -1.21 | -0.97 | -0.99 | — |
| Shares | 49.5M | 49.5M | 49.5M | 47.1M | -4.7% | 57.0M | — | — | — |
| Debt | 1.7M | 1.3M | 0.8M | 0 | -29.2% | — | — | — | — |
| Equity | 158.4M | 105.2M | 52.5M | 136.3M | -4.9% | — | — | — | — |
| Op CF | -49.6M | -59.7M | -59.5M | -97.4M | — | -69.3M | — | — | — |
| Inv CF | -132.9M | 83.2M | 25.2M | 11.9M | — | — | — | — | — |
| Fin CF | 72.6M | 0.3M | 0.1M | 94.4M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of WHWK are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| WHWK | Whitehawk Therapeutics, Inc.(you) | $263M | 32 | Sell |
| IKT | Inhibikase Therapeutics, Inc. | $336M | 31 | Sell |
| NAGE | Niagen Bioscience, Inc. | $260M | 38 | Hold |
| ANTX | AN2 Therapeutics, Inc. | $211M | 35 | Sell |
| ACOG | Alpha Cognition Inc. Common Stock | $199M | 34 | Sell |
| DTIL | Precision BioSciences, Inc. | $215M | 28 | Sell |
| PALI | Palisade Bio, Inc. | $349M | 29 | Sell |
| ABEO | Abeona Therapeutics Inc. | $339M | 37 | Hold |
| IMUX | Immunic, Inc. | $210M | 26 | Sell |
| IRD | Opus Genetics, Inc. | $307M | 22 | Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%